Vermillion Announces Cigna Preferred Contract Coverage for OVA1, OVERA and Genetics Testing

For a pdf of this press release click here

AUSTIN, Texas, March 27, 2020 – Vermillion, Inc. (NASDAQ: VRML), a bioinformatics-based women’s health company focused on gynecologic disease, announced yesterday that its wholly owned subsidiary, ASPiRA Labs, has signed a national preferred
agreement with Cigna. This contract includes OVA1, (Multivariate Index Assay, MIA) our ACOG endorsed ovarian cancer risk assessment test, as well as OVERA and all genetic testing offered by Aspira. This agreement with Cigna will expand ASPiRA Labs contracted coverage by an additional 16 million lives.

“We are excited to add one of the major national payers to the ASPiRA contracted payer network, allowing another 16 million lives to have access to all of ASPiRA’s testing as an in-network benefit”, said Valerie Palmieri, CEO of Vermillion. “This national agreement with Cigna is a major milestone for Vermillion and patients, as OVA1 continues on its trajectory to becoming the standard of care for ovarian cancer risk assessment. OVA1 is an FDA-cleared technology to assess ovarian cancer risk in women with pelvic masses inclusive of all ages, all stages. No comparable product exists on the market, with outstanding performance in premenopausal women, all cancer types and African American women.”